Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

February 8, 2024

https://www.globenewswire.com/news-release/2024/02/08/2825920/30555/en/Amedisys-Offers-Molecular-Testing-for-Rapid-and-Accurate-Infection-Diagnosis.html

BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes.

Read more at globenewswire.com

Related news for (AMED)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.